Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.31 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20023729 | 1.00 | PDGFRB (0.41) | PDGFRBPDGFRAPIK3CAMTORHTR2A | |
| SCHEMBL13356662 | 0.85 | PDGFRB (0.42) | PDGFRBPDGFRAITGAVITGB6ITGB8 | |
| SCHEMBL24634995 | 0.73 | PIK3CA (0.33) | PIK3CAMTOR | |
| SCHEMBL30239388 | 0.73 | CYP1A2 (0.53) | PDGFRBPDGFRA | |
| SCHEMBL20023742 | 0.73 | CYP1A2 (0.53) | PDGFRBPDGFRA | |
| SCHEMBL1253863 | 0.73 | CYP1A2 (0.53) | PDGFRBPDGFRA | |
| SCHEMBL28467592 | 0.73 | CYP1A2 (0.53) | PDGFRBPDGFRA | |
| SCHEMBL30447104 | 0.73 | CYP1A2 (0.53) | PDGFRBPDGFRA | |
| SCHEMBL30889392 | 0.72 | ADRB2 (0.46) | PDGFRBPDGFRAHTR2AHTR2C | |
| SCHEMBL30315766 | 0.72 | ADRB2 (0.46) | PDGFRBPDGFRAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528813-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEV 1 INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2024-11-28 | — | — | US | disclosed |
| CN-116854693-A | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-109996546-B | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-06-27 | — | — | CN | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | PDGFRB 739/4885PDGFRA 683/4885PIK3CA 1602/4885 |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | PDGFRB 739/4885PDGFRA 683/4885PIK3CA 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.